Search for COVID-19 and Reopening Information Here

Is the monkeypox (hMPXV) vaccine available in New Jersey?

Last Updated: 08/19/2022

Monkeypox (hMPXV) is a disease that can affect anyone, regardless of gender or sexual orientation. The virus can cause flu-like symptoms, swollen lymph nodes, and rash. Monkeypox (hMPXV) can spread to any individual from anyone who has the virus through direct contact with rashes or scabs, respiratory droplets from face-to-face interactions, or close, intimate contact.

There is a limited supply of the JYNNEOS monkeypox (hMPXV) vaccine in New Jersey. Monkeypox (hMPXV) vaccinations are provided to eligible residents at no charge to the individual.

Vaccine Access for Residents with Known Exposure

For residents with known exposure to a person with monkeypox (hMPXV), the two-dose regimen of the monkeypox (hMPXV) vaccine for Post-Exposure Prophylaxis (PEP) is available through their local health department. Anyone with a known exposure within the past 14 days should contact their health care provider or local health department regarding testing and vaccine eligibility. Local health departments will conduct contact tracing and offer the vaccine to anyone identified as a close contact.

Vaccine Access for Residents Without a Confirmed Exposure

For those without a confirmed exposure who believe they may have been exposed or are at high risk for having been exposed to monkeypox (hMPXV), the vaccine is available through community vaccination sites.

Residents are eligible to receive a vaccine at community sites if they meet one of the following criteria:

  • People who attended an event where known monkeypox (hMPXV) exposure occurred within the past 14 days.
  • People who had multiple sexual partners in the past 14 days in areas where monkeypox (hMPXV) has been reported.

Vaccination is available for eligible residents at the following locations by appointment only:

North Jersey

Central Jersey

South Jersey

Individuals with a condition that weakens the immune system or a history of atopic dermatitis or eczema are at increased risk for severe disease and should be a high-priority for vaccination if they have exposure risk.